SCHEMBL4197243

SCHEMBL4197243

NC(=O)/C=C/c1cccs1

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.71
ABCG2 Q9UNQ0 2/20 0.59
SMN1; SMN2 Q16637 6/20 0.57
ALDH1A1 P00352 3/20 0.57
MAPT P10636 3/20 0.57
LMNA P02545 2/20 0.57
NPC1 O15118 3/20 0.54
RAB9A P51151 3/20 0.54
KDM4E B2RXH2 2/20 0.54
MEN1 O00255 1/20 0.54
PSMD14 O00487 1/20 0.54
TP53 P04637 1/20 0.54
GLA P06280 1/20 0.54
HTT P42858 1/20 0.54
KMT2A Q03164 1/20 0.54
HPGD P15428 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1086015 1.00 HCAR2 (0.71) HCAR2ABCG2SMN1; SMN2ALDH1A1MAPT
SCHEMBL5598744 0.85 HCAR2 (0.74) HCAR2ABCG2SMN1; SMN2ALDH1A1MAPT
SCHEMBL5598741 0.85 HCAR2 (0.74) HCAR2ABCG2SMN1; SMN2ALDH1A1MAPT
SCHEMBL600082 0.83 HCAR2 (1.00) HCAR2ABCG2SMN1; SMN2ALDH1A1MAPT
SCHEMBL143282 0.83 HCAR2 (1.00) HCAR2ABCG2SMN1; SMN2ALDH1A1MAPT
SCHEMBL3707176 0.83
SCHEMBL1862223 0.82 HCAR2 (0.69) HCAR2ABCG2SMN1; SMN2ALDH1A1MAPT
SCHEMBL3382206 0.82 HCAR2 (0.69) HCAR2ABCG2SMN1; SMN2ALDH1A1MAPT
SCHEMBL20273260 0.82 HCAR2 (0.69) HCAR2ABCG2SMN1; SMN2ALDH1A1MAPT
SCHEMBL369705 0.82 HCAR2 (0.69) HCAR2ABCG2SMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1217943-C New use and novel N-azabicyclo-amide derivatives ASTRAZENECA AB (SE) 2005-09-07 CN claimed
CN-1423651-A Novel use and novel N-azabicyclo-amide derivatives ASTRAZENECA AB (SE) 2003-06-11 CN claimed
US-20200024294-A1 Organic metal compound and organic light-emitting device INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2020-01-23 US disclosed
EP-2573078-B1 ACRYLAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS CHINESE PLA GENERAL HOSPITAL (CN) 2016-11-02 EP disclosed
EP-2573078-B1 ACRYLAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS CHINESE PLA GENERAL HOSPITAL (CN) 2016-11-02 EP disclosed
US-9439881-B2 Acrylamide compounds and use thereof for inhibiting apoptosis CHINESE PLA GENERAL HOSPITAL (CN) 2016-09-13 US disclosed
US-9439881-B2 Acrylamide compounds and use thereof for inhibiting apoptosis CHINESE PLA GENERAL HOSPITAL (CN) 2016-09-13 US disclosed
US-9439881-B2 Acrylamide compounds and use thereof for inhibiting apoptosis CHINESE PLA GENERAL HOSPITAL (CN) 2016-09-13 US disclosed
US-20160038445-A1 ACRYLAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS CHINESE PLA GENERAL HOSPITAL (CN) 2016-02-11 US disclosed
US-20160038445-A1 ACRYLAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS CHINESE PLA GENERAL HOSPITAL (CN) 2016-02-11 US disclosed
US-20160038445-A1 ACRYLAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS CHINESE PLA GENERAL HOSPITAL (CN) 2016-02-11 US disclosed
US-20130158022-A1 Acrylamide Compounds And Use Thereof For Inhibiting Apoptosis CHINESE PLA GENERAL HOSPITAL (CN) 2013-06-20 US disclosed
US-20130158022-A1 Acrylamide Compounds And Use Thereof For Inhibiting Apoptosis CHINESE PLA GENERAL HOSPITAL (CN) 2013-06-20 US disclosed
EP-2573078-A1 ACRYLAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS Chinese PLA General Hospital (CN) 2013-03-27 EP disclosed
EP-2573078-A1 ACRYLAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS Chinese PLA General Hospital (CN) 2013-03-27 EP disclosed
CN-102241673-A Acrylamide compounds and medicinal uses thereof CHINESE PLA GENERAL HOSPITAL 2011-11-16 CN disclosed
EP-2233484-A2 Oxazolidinone derivatives having a 7-membered heterocyclic ring Research Foundation Itsuu Laboratory (JP) 2010-09-29 EP disclosed
US-20090192180-A1 Alpha-7 Nicotinic Receptor Agonists and Statins In Combination KEITH RICHARD 2009-07-30 US disclosed
CN-1217943-C New use and novel N-azabicyclo-amide derivatives ASTRAZENECA AB (SE) 2005-09-07 CN disclosed
CN-1423651-A Novel use and novel N-azabicyclo-amide derivatives ASTRAZENECA AB (SE) 2003-06-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160038445-A1 ACRYLAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS BAX, API5, BCL2 HCAR2 1531/4885ABCG2 283/4885SMN1; SMN2 404/4885
US-20130158022-A1 Acrylamide Compounds And Use Thereof For Inhibiting Apoptosis BAX, API5, BCL2 HCAR2 1531/4885ABCG2 283/4885SMN1; SMN2 404/4885
US-20200024294-A1 Organic metal compound and organic light-emitting device ORC3, C1S, C1R HCAR2 3673/4885ABCG2 3515/4885SMN1; SMN2 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.